Category:
Active Pharmaceutical Ingredients
CAS NO:
1201438-56-3
Standard:
In-house Standards,
Oncology Blood Cancer
Duvelisib (IPI-145) is a dual PI3K inhibitor developed for oncology. Its molecular formula is C26H27N7O2 with CAS 908413-49-6. The synthesis involves complex heterocyclic coupling.
Contraindicated in severe hepatic impairment. Requires strict storage below 25°C in dry conditions. Monitor for colitis and pneumonitis during clinical administration.